Development of a homogeneous screening assay for automated detection of antiviral agents active against severe acute respiratory syndrome-associated coronavirus.
Identifieur interne : 002751 ( PubMed/Checkpoint ); précédent : 002750; suivant : 002752Development of a homogeneous screening assay for automated detection of antiviral agents active against severe acute respiratory syndrome-associated coronavirus.
Auteurs : Tania Ivens [Belgique] ; Christel Van Den Eynde ; Koen Van Acker ; Erik Nijs ; Géry Dams ; Eva Bettens ; Asa Ohagen ; Rudi Pauwels ; Kurt HertogsSource :
- Journal of virological methods [ 0166-0934 ] ; 2005.
Descripteurs français
- KwdFr :
- MESH :
- analyse : Antiviraux.
- métabolisme : Antiviraux.
- pharmacologie : Antiviraux.
- physiologie : Virus du SRAS.
- Antiviraux, Lignée cellulaire, Protéines à fluorescence verte, Réplication virale, Virus du SRAS, Évaluation préclinique de médicament.
English descriptors
- KwdEn :
- MESH :
- chemical , analysis : Antiviral Agents.
- chemical , chemistry : Antiviral Agents.
- chemical , metabolism : Antiviral Agents.
- chemical , pharmacology : Antiviral Agents.
- drug effects : SARS Virus, Virus Replication.
- physiology : SARS Virus.
- Cell Line, Drug Evaluation, Preclinical, Green Fluorescent Proteins.
Abstract
The severity and global spread of the 2003 outbreak of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) highlighted the risks to human health posed by emerging viral diseases and emphasized the need for specific therapeutic agents instead of relying on existing broadly active antiviral compounds. The development of rapid screening assays is essential for antiviral drug discovery. Thus, a screening system for anti-SARS-CoV agents was developed, which evaluated compound potency, specificity and cytotoxicity at the initial screening phase. Cell lines were engineered to constitutively express an enhanced green fluorescent protein (EGFP) and used to detect (1) antiviral potency in SARS-CoV infection tests; (2) antiviral specificity in tests using the porcine coronavirus transmissible gastroenteritis virus (TGEV); and (3) cytotoxicity in the same assays without virus challenge. The assay system involves minimal manipulation after assay set-up, facilitates automated read-out and minimizes risks associated with hazardous viruses. The suitability of this assay system in drug discovery was demonstrated by screening of 3388 small molecule compounds. The results show that these assays can be applied to high-throughput screening for identification of inhibitors selectively active against SARS-CoV.
DOI: 10.1016/j.jviromet.2005.05.010
PubMed: 15961169
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:15961169Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development of a homogeneous screening assay for automated detection of antiviral agents active against severe acute respiratory syndrome-associated coronavirus.</title><author><name sortKey="Ivens, Tania" sort="Ivens, Tania" uniqKey="Ivens T" first="Tania" last="Ivens">Tania Ivens</name><affiliation wicri:level="1"><nlm:affiliation>Tibotec BVBA, Lead Discovery Operations, Gen De Wittelaan L 11B 3, Mechelen 2800, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Tibotec BVBA, Lead Discovery Operations, Gen De Wittelaan L 11B 3, Mechelen 2800</wicri:regionArea><wicri:noRegion>Mechelen 2800</wicri:noRegion></affiliation></author><author><name sortKey="Van Den Eynde, Christel" sort="Van Den Eynde, Christel" uniqKey="Van Den Eynde C" first="Christel" last="Van Den Eynde">Christel Van Den Eynde</name></author><author><name sortKey="Van Acker, Koen" sort="Van Acker, Koen" uniqKey="Van Acker K" first="Koen" last="Van Acker">Koen Van Acker</name></author><author><name sortKey="Nijs, Erik" sort="Nijs, Erik" uniqKey="Nijs E" first="Erik" last="Nijs">Erik Nijs</name></author><author><name sortKey="Dams, Gery" sort="Dams, Gery" uniqKey="Dams G" first="Géry" last="Dams">Géry Dams</name></author><author><name sortKey="Bettens, Eva" sort="Bettens, Eva" uniqKey="Bettens E" first="Eva" last="Bettens">Eva Bettens</name></author><author><name sortKey="Ohagen, Asa" sort="Ohagen, Asa" uniqKey="Ohagen A" first="Asa" last="Ohagen">Asa Ohagen</name></author><author><name sortKey="Pauwels, Rudi" sort="Pauwels, Rudi" uniqKey="Pauwels R" first="Rudi" last="Pauwels">Rudi Pauwels</name></author><author><name sortKey="Hertogs, Kurt" sort="Hertogs, Kurt" uniqKey="Hertogs K" first="Kurt" last="Hertogs">Kurt Hertogs</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2005">2005</date><idno type="RBID">pubmed:15961169</idno><idno type="pmid">15961169</idno><idno type="doi">10.1016/j.jviromet.2005.05.010</idno><idno type="wicri:Area/PubMed/Corpus">002684</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002684</idno><idno type="wicri:Area/PubMed/Curation">002684</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002684</idno><idno type="wicri:Area/PubMed/Checkpoint">002751</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002751</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Development of a homogeneous screening assay for automated detection of antiviral agents active against severe acute respiratory syndrome-associated coronavirus.</title><author><name sortKey="Ivens, Tania" sort="Ivens, Tania" uniqKey="Ivens T" first="Tania" last="Ivens">Tania Ivens</name><affiliation wicri:level="1"><nlm:affiliation>Tibotec BVBA, Lead Discovery Operations, Gen De Wittelaan L 11B 3, Mechelen 2800, Belgium.</nlm:affiliation><country xml:lang="fr">Belgique</country><wicri:regionArea>Tibotec BVBA, Lead Discovery Operations, Gen De Wittelaan L 11B 3, Mechelen 2800</wicri:regionArea><wicri:noRegion>Mechelen 2800</wicri:noRegion></affiliation></author><author><name sortKey="Van Den Eynde, Christel" sort="Van Den Eynde, Christel" uniqKey="Van Den Eynde C" first="Christel" last="Van Den Eynde">Christel Van Den Eynde</name></author><author><name sortKey="Van Acker, Koen" sort="Van Acker, Koen" uniqKey="Van Acker K" first="Koen" last="Van Acker">Koen Van Acker</name></author><author><name sortKey="Nijs, Erik" sort="Nijs, Erik" uniqKey="Nijs E" first="Erik" last="Nijs">Erik Nijs</name></author><author><name sortKey="Dams, Gery" sort="Dams, Gery" uniqKey="Dams G" first="Géry" last="Dams">Géry Dams</name></author><author><name sortKey="Bettens, Eva" sort="Bettens, Eva" uniqKey="Bettens E" first="Eva" last="Bettens">Eva Bettens</name></author><author><name sortKey="Ohagen, Asa" sort="Ohagen, Asa" uniqKey="Ohagen A" first="Asa" last="Ohagen">Asa Ohagen</name></author><author><name sortKey="Pauwels, Rudi" sort="Pauwels, Rudi" uniqKey="Pauwels R" first="Rudi" last="Pauwels">Rudi Pauwels</name></author><author><name sortKey="Hertogs, Kurt" sort="Hertogs, Kurt" uniqKey="Hertogs K" first="Kurt" last="Hertogs">Kurt Hertogs</name></author></analytic><series><title level="j">Journal of virological methods</title><idno type="ISSN">0166-0934</idno><imprint><date when="2005" type="published">2005</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral Agents (analysis)</term><term>Antiviral Agents (chemistry)</term><term>Antiviral Agents (metabolism)</term><term>Antiviral Agents (pharmacology)</term><term>Cell Line</term><term>Drug Evaluation, Preclinical</term><term>Green Fluorescent Proteins</term><term>SARS Virus (drug effects)</term><term>SARS Virus (physiology)</term><term>Virus Replication (drug effects)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Antiviraux ()</term><term>Antiviraux (analyse)</term><term>Antiviraux (métabolisme)</term><term>Antiviraux (pharmacologie)</term><term>Lignée cellulaire</term><term>Protéines à fluorescence verte</term><term>Réplication virale ()</term><term>Virus du SRAS ()</term><term>Virus du SRAS (physiologie)</term><term>Évaluation préclinique de médicament</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="chemistry" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term><term>Virus Replication</term></keywords><keywords scheme="MESH" qualifier="métabolisme" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Cell Line</term><term>Drug Evaluation, Preclinical</term><term>Green Fluorescent Proteins</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Antiviraux</term><term>Lignée cellulaire</term><term>Protéines à fluorescence verte</term><term>Réplication virale</term><term>Virus du SRAS</term><term>Évaluation préclinique de médicament</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The severity and global spread of the 2003 outbreak of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) highlighted the risks to human health posed by emerging viral diseases and emphasized the need for specific therapeutic agents instead of relying on existing broadly active antiviral compounds. The development of rapid screening assays is essential for antiviral drug discovery. Thus, a screening system for anti-SARS-CoV agents was developed, which evaluated compound potency, specificity and cytotoxicity at the initial screening phase. Cell lines were engineered to constitutively express an enhanced green fluorescent protein (EGFP) and used to detect (1) antiviral potency in SARS-CoV infection tests; (2) antiviral specificity in tests using the porcine coronavirus transmissible gastroenteritis virus (TGEV); and (3) cytotoxicity in the same assays without virus challenge. The assay system involves minimal manipulation after assay set-up, facilitates automated read-out and minimizes risks associated with hazardous viruses. The suitability of this assay system in drug discovery was demonstrated by screening of 3388 small molecule compounds. The results show that these assays can be applied to high-throughput screening for identification of inhibitors selectively active against SARS-CoV.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15961169</PMID><DateCompleted><Year>2005</Year><Month>11</Month><Day>29</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0166-0934</ISSN><JournalIssue CitedMedium="Print"><Volume>129</Volume><Issue>1</Issue><PubDate><Year>2005</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Journal of virological methods</Title><ISOAbbreviation>J. Virol. Methods</ISOAbbreviation></Journal><ArticleTitle>Development of a homogeneous screening assay for automated detection of antiviral agents active against severe acute respiratory syndrome-associated coronavirus.</ArticleTitle><Pagination><MedlinePgn>56-63</MedlinePgn></Pagination><Abstract><AbstractText>The severity and global spread of the 2003 outbreak of the severe acute respiratory syndrome-associated coronavirus (SARS-CoV) highlighted the risks to human health posed by emerging viral diseases and emphasized the need for specific therapeutic agents instead of relying on existing broadly active antiviral compounds. The development of rapid screening assays is essential for antiviral drug discovery. Thus, a screening system for anti-SARS-CoV agents was developed, which evaluated compound potency, specificity and cytotoxicity at the initial screening phase. Cell lines were engineered to constitutively express an enhanced green fluorescent protein (EGFP) and used to detect (1) antiviral potency in SARS-CoV infection tests; (2) antiviral specificity in tests using the porcine coronavirus transmissible gastroenteritis virus (TGEV); and (3) cytotoxicity in the same assays without virus challenge. The assay system involves minimal manipulation after assay set-up, facilitates automated read-out and minimizes risks associated with hazardous viruses. The suitability of this assay system in drug discovery was demonstrated by screening of 3388 small molecule compounds. The results show that these assays can be applied to high-throughput screening for identification of inhibitors selectively active against SARS-CoV.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ivens</LastName><ForeName>Tania</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Tibotec BVBA, Lead Discovery Operations, Gen De Wittelaan L 11B 3, Mechelen 2800, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van den Eynde</LastName><ForeName>Christel</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Van Acker</LastName><ForeName>Koen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Nijs</LastName><ForeName>Erik</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Dams</LastName><ForeName>Géry</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Bettens</LastName><ForeName>Eva</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Ohagen</LastName><ForeName>Asa</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Pauwels</LastName><ForeName>Rudi</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Hertogs</LastName><ForeName>Kurt</ForeName><Initials>K</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Virol Methods</MedlineTA><NlmUniqueID>8005839</NlmUniqueID><ISSNLinking>0166-0934</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>147336-22-9</RegistryNumber><NameOfSubstance UI="D049452">Green Fluorescent Proteins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004353" MajorTopicYN="N">Drug Evaluation, Preclinical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D049452" MajorTopicYN="N">Green Fluorescent Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>01</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2005</Year><Month>04</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2005</Year><Month>05</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>6</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>12</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>6</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15961169</ArticleId><ArticleId IdType="pii">S0166-0934(05)00161-8</ArticleId><ArticleId IdType="doi">10.1016/j.jviromet.2005.05.010</ArticleId><ArticleId IdType="pmc">PMC7112772</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virology. 1990 Apr;175(2):556-61</Citation><ArticleIdList><ArticleId IdType="pubmed">1691563</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Virus Res. 2001 Oct 30;78(1-2):67-78</Citation><ArticleIdList><ArticleId IdType="pubmed">11520581</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 2004 Jul 16;279(29):30514-22</Citation><ArticleIdList><ArticleId IdType="pubmed">15123674</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Antiviral Res. 1999 Aug;43(1):23-35</Citation><ArticleIdList><ArticleId IdType="pubmed">10480261</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 1986 Nov;83(21):8333-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2430286</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2003 Nov 27;426(6965):450-4</Citation><ArticleIdList><ArticleId IdType="pubmed">14647384</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>JAMA. 2003 Oct 1;290(13):1695-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14519691</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 2003 Sep;84(Pt 9):2305-2315</Citation><ArticleIdList><ArticleId IdType="pubmed">12917450</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2004 Apr;10(4):581-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15200845</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Int J Infect Dis. 2004 Jul;8(4):223-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15234326</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 1992 May 29;185(1):85-90</Citation><ArticleIdList><ArticleId IdType="pubmed">1599491</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gen Virol. 2004 Jun;85(Pt 6):1717-1725</Citation><ArticleIdList><ArticleId IdType="pubmed">15166457</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2004 Oct;78(20):11334-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15452254</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Jul 6;101(27):10012-7</Citation><ArticleIdList><ArticleId IdType="pubmed">15226499</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Pharmacotherapy. 2001 Nov;21(11):1352-63</Citation><ArticleIdList><ArticleId IdType="pubmed">11714208</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Thorax. 2004 Mar;59(3):252-6</Citation><ArticleIdList><ArticleId IdType="pubmed">14985565</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biol Chem. 2003 Sep 12;278(37):35755-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12824191</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2004 Mar 20;363(9413):938-47</Citation><ArticleIdList><ArticleId IdType="pubmed">15043961</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Biomed Mater Res. 1999 Dec 15;47(4):516-22</Citation><ArticleIdList><ArticleId IdType="pubmed">10497286</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Gastroenterol Hepatol. 2003 Apr;18(4):393-403</Citation><ArticleIdList><ArticleId IdType="pubmed">12653887</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2002 Dec;76(24):12491-502</Citation><ArticleIdList><ArticleId IdType="pubmed">12438575</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Jun 14;361(9374):2045-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12814717</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 May 10;361(9369):1615-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12747883</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biochem Biophys Res Commun. 2004 Jun 4;318(3):719-25</Citation><ArticleIdList><ArticleId IdType="pubmed">15144898</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Belgique</li></country></list><tree><noCountry><name sortKey="Bettens, Eva" sort="Bettens, Eva" uniqKey="Bettens E" first="Eva" last="Bettens">Eva Bettens</name><name sortKey="Dams, Gery" sort="Dams, Gery" uniqKey="Dams G" first="Géry" last="Dams">Géry Dams</name><name sortKey="Hertogs, Kurt" sort="Hertogs, Kurt" uniqKey="Hertogs K" first="Kurt" last="Hertogs">Kurt Hertogs</name><name sortKey="Nijs, Erik" sort="Nijs, Erik" uniqKey="Nijs E" first="Erik" last="Nijs">Erik Nijs</name><name sortKey="Ohagen, Asa" sort="Ohagen, Asa" uniqKey="Ohagen A" first="Asa" last="Ohagen">Asa Ohagen</name><name sortKey="Pauwels, Rudi" sort="Pauwels, Rudi" uniqKey="Pauwels R" first="Rudi" last="Pauwels">Rudi Pauwels</name><name sortKey="Van Acker, Koen" sort="Van Acker, Koen" uniqKey="Van Acker K" first="Koen" last="Van Acker">Koen Van Acker</name><name sortKey="Van Den Eynde, Christel" sort="Van Den Eynde, Christel" uniqKey="Van Den Eynde C" first="Christel" last="Van Den Eynde">Christel Van Den Eynde</name></noCountry><country name="Belgique"><noRegion><name sortKey="Ivens, Tania" sort="Ivens, Tania" uniqKey="Ivens T" first="Tania" last="Ivens">Tania Ivens</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002751 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 002751 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:15961169
|texte= Development of a homogeneous screening assay for automated detection of antiviral agents active against severe acute respiratory syndrome-associated coronavirus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:15961169" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |